Clinical trials: Alcoholic Liver Disease
NAFLD, NASH
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
- Trial name
- NCT06410924
- Testing
- DD01
- Where
- 12 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neuraly, Inc.
Alcoholic Hepatitis, Alcoholic Cirrhosis
Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis
The study is aimed to evaluate the additional role of ciprofloxacin therapy in severe alcoholic hepatitis combined to prednisolone therapy in an open-label placebo controlled manner.
- Trial name
- NCT02326103
- Testing
- Ciprofloxacin
- Where
- Finland
- Volunteers
- 22 people
- Sponsor
- University of Helsinki
Hepatitis, Alcoholic
Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).
The primary objective of this study is to determine the prevalence of AH in addition to its clinical characteristics and in-hospital mortality of patients that are hospitalized for AH in different hospitals across Latin American…
- Trial name
- NCT04142723
- Testing
- blood withdraw
- Where
- Chile
- Volunteers
- 1,000 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Non-alcoholic Fatty Liver Disease (NAFLD)
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
Metformin is being compared to exercise and diet modifications. The researchers are interested in learning if the addition of metformin to lifestyle modifications is more helpful in treating the condition or disorder.
- Trial name
- NCT02457286
- Testing
- Metformin, Lifestyle modifications, Fibroscan device (Echosens)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Northwell Health
NAFLD
Non-alcoholic Fatty Liver Disease and Its Treatment
Dipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
- Trial name
- NCT05480007
- Testing
- sitagliptin and metformin, Sitagliptin, Metformin
- Volunteers
- 68 people
- Sponsor
- Shanghai 10th People's Hospital
Non-alcoholic Fatty Liver Disease
Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents
This research study intends to learn about whether early intervention can help to prevent non-alcoholic fatty liver disease (NAFLD) in adolescents.
- Trial name
- NAFLD (NCT02116192)
- Testing
- Experimental: Low-fructose, reduced carbohydrate diet, General Healthy Diet
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Wisconsin, Madison
Non-Alcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Trial name
- NCT03884075
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Non Alcoholic Steatohepatitis
Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)
The study was being conducted in order to assess the pharmacokinetics and the safety of elafibranor following once daily administration of two dose levels of elafibranor (80 milligrams [mg] and 120mg) during 3 months in children…
- Trial name
- NCT03883607
- Testing
- Elafibranor 80mg, Elafibranor 120mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Genfit
NAFLD
Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease
The major adverse health consequences of obesity occur only when non-alcoholic fatty liver disease (NAFLD) also develops. NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids.
- Trial name
- NCT02558530
- Testing
- Low carbohydrate diet
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Non-alcoholic Fatty Liver Disease
Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease
The aim of study was to evaluate the effect of helicobacter pylori eradication on liver function tests, lipid profile, homeostasis model assessment-IR (HOMA-IR) index, and anthropometric measurements (body mass index and waist…
- Trial name
- NCT01759628
- Testing
- H.pylori eradication
- Where
- Iran
- Volunteers
- 100 people
- Sponsor
- Tehran University of Medical Sciences
Non-Alcoholic Fatty Liver Disease
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT06717828
- Testing
- Tai Chi Exercise, Regular Exercise, Control
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Provincial Hospital
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Non-Alcoholic Fatty Liver Disease
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NAFLD encompasses the entire spectrum of Fatty liver disease in individuals without significant alcohol consumption, ranging from fatty liver to steatohepatitis to cirrhosis.
- Trial name
- NCT05073588
- Testing
- Indo Mediterranean diet, Calorie restricted diet
- Where
- India
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Institute of Liver and Biliary Sciences, India
NAFLD, TYPE 2 DIABETES
Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents
The current project is designed as a 30-day pilot trial to demonstrate the safety and tolerability of resveratrol therapy in overweight adolescents to decrease liver fat, and improve insulin sensitivity to prevent type 2 diabetes.
- Conditions
- NAFLD, TYPE 2 DIABETES, METABOLIC SYNDROME
- Trial name
- NCT02216552
- Testing
- Resveratrol
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Manitoba
Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD…
- Trial name
- NCT01030484
- Where
- 8 sites in United States
- Volunteers
- 2,501 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Alcohol Associated Hepatitis
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
The purpose of this trial is to assess dose related safety, efficacy, and pharmacokinetics (PK) of INT-787 in participants with severe alcohol-associated hepatitis (sAH).
- Trial name
- FRESH (NCT05639543)
- Testing
- INT-787
- Where
- 29 sites in United States, France and 1 more
- Volunteers
- 67 people
- Sponsor
- Intercept Pharmaceuticals
Non Alcoholic Fatty Liver Disease
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
The central hypothesis of this proposal is that a reduction in hepatic mitochondrial function is the main pathophysiology behind NAFLD (Non-Alcoholic Fatty Liver Disease) and NASH (Non alcoholic steatohepatitis).
- Trial name
- NCT01327443
- Testing
- Weight loss, Exercise
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Missouri-Columbia
Liver Diseases
Nonalcoholic Fatty Liver Disease (NAFLD) Database 3
The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis.
- Trial name
- NCT04454463
- Where
- 16 sites in United States
- Volunteers
- 1,649 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Gestational Diabetes Mellitus in Pregnancy
The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes
The thought is that Non-Alcoholic Fatty Liver Disease (NAFLD) plays a key role in the progression to prediabetes/T2DM in those with a history of Gestational Diabetes (GDM).
- Trial name
- NCT01855386
- Testing
- Subjects with Gestational Diabetes, Controls without Gestational Diabetes
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.